{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:45:13Z","timestamp":1761871513107,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003286","name":"Kuwait Foundation for the Advancement of Sciences","doi-asserted-by":"publisher","award":["P11613MM08"],"award-info":[{"award-number":["P11613MM08"]}],"id":[{"id":"10.13039\/501100003286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.clml.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T20:17:28Z","timestamp":1616271448000},"page":"483-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"21","author":[{"given":"Salem H.","family":"Alshemmari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshmi","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Ameen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazyad","family":"Almazyad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.03.005_bib0001","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.005_bib0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.03.005_bib0003","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.03.005_bib0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.03.005_bib0005","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","article-title":"The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review","volume":"96","author":"Devendra","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.03.005_bib0006","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.03.005_bib0007","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","article-title":"Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia","volume":"93","author":"Chen","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.03.005_bib0008","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2014.109199","article-title":"Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients","volume":"99","author":"Chun","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.03.005_bib0009","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.005_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.005_bib0011","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.005_bib0012","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.03.005_bib0013","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13104-019-4321-1","article-title":"Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada","volume":"12","author":"Heppner","year":"2019","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.clml.2021.03.005_bib0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrclinonc.2014.16","article-title":"Genetics: CALR mutations and a new diagnostic algorithm for MPN","volume":"11","author":"Tefferi","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2021.03.005_bib0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.03.005_bib0016","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.03.005_bib0017","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.03.005_bib0018","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.03.005_bib0019","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.03.005_bib0021","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2021.03.005_bib0022","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.005_bib0023","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2021.03.005_bib0024","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2016.149559","article-title":"Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group","volume":"102","author":"Holly","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.03.005_bib0025","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0039-1693477","article-title":"Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms","volume":"45","author":"Arachchillage","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2021.03.005_bib0026","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2016.280","article-title":"A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation","volume":"31","author":"Kollmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.03.005_bib0027","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.03.005_bib0028","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41408-017-0010-2","article-title":"CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles","volume":"7","author":"Zini","year":"2017","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:46Z","timestamp":1761870946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2152265021001063"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.03.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}